Lilly announced meaningful price cuts to its tirzepatide-based obesity drug Zepbound, reducing out-of-pocket costs on its LillyDirect platform to as low as $299 for the starter dose and $449 for higher doses, just weeks after negotiating a separate price-cut agreement with the Trump Administration to secure Medicare access and tariff relief
It helps keep blood sugar steady and reduces appetite
Potential risks include inadequate disease management, unpredictable side effects and interactions with other medications. Dont be fooled by social media Its easy to get caught up in what youre seeing and hearing online, but if it seems too good to be true it probably is
Wegovy (semaglutide) is a GLP-1 receptor agonist licensed in the UK for weight management in adults with obesity or overweight with weight-related comorbidities
Studies suggest that supraphysiological doses of exogenous GLP-2 has a significant inhibitory effect on bone resorption, however the specific mechanism by which GLP-2 influences bone metabolism remains unknown
Data showcases that children with obesity are five times more likely to have obesity in their adulthood than their healthy-weight counterparts